BAX 855: Phase I data

Top-line data from an open-label Phase I trial in 19 previously-treated patients aged 18 years and older with severe hemophilia A showed that BAX 855 had a 1.5-fold higher half-life compared to Advate octocog alfa. No patients developed inhibitors or had allergic reactions. This quarter, Baxter plans to start the open-label, U.S. Phase II/III PROLONG-ATE trial to evaluate BAX 855 for prophylaxis and on-demand treatment in over 100 previously-treated patients with severe hemophilia A. ...